Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study

Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study

The ability of early (first weeks of treatment) ctDNA kinetics to identify primary resistance to anti-PD1 immunotherapies was evaluated with a validation cohort of 49 patients treated with anti‑PD1 for metastatic BRAF or NRAS-mutated melanoma, alone and pooled with the 53 patients from a previously...

Full description

Bibliographic Details
Main Authors: Guillaume Herbreteau, Audrey Vallée, Anne-Chantal Knol, Sandrine Théoleyre, Gaëlle Quéreux, Emilie Varey, Amir Khammari, Brigitte Dréno, Marc G. Denis
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
immunotherapy
anti-PD1
cell-free DNA
circulating tumor DNA
melanoma
metastatic melanoma
Online Access:https://www.mdpi.com/2072-6694/13/8/1826

Internet

https://www.mdpi.com/2072-6694/13/8/1826

Similar Items